Legend Biotech (LEGN) Amortization (2020 - 2025)

Legend Biotech has reported Amortization for 6 years, with the latest figure at -$20.8 million in Q3 2025.

• For the quarter ending Q3 2025, Amortization rose 57.67% year-over-year to -$20.8 million; the trailing twelve-month figure through Sep 2025 stood at -$99.1 million (up 55.8% YoY), and the FY2022 full-year result was -$402.5 million, down 11.37% from the prior year.
• Amortization for Q3 2025 stood at -$20.8 million, down from $3.5 million in the prior quarter.
• The five-year high for Amortization was $3.5 million in Q2 2025, with the low at -$402.5 million in Q4 2022.
• Historically, Amortization has averaged -$106.4 million across 5 years, with a median of -$74.2 million in 2023.
• Annual changes were most pronounced in 2023 — Amortization slumped 72.52% — and 2025, when it soared 137.88%.
• Legend Biotech's Amortization stood at -$361.4 million in 2021, then retreated by 11.37% to -$402.5 million in 2022, then soared by 81.58% to -$74.2 million in 2023, then jumped by 33.73% to -$49.1 million in 2024, then jumped by 57.67% to -$20.8 million in 2025.
• The last three Amortization figures came in at -$20.8 million (Q3 2025), $3.5 million (Q2 2025), and -$32.7 million (Q1 2025), per Business Quant data.